Recent Updates
Recently added Catalysts
CELC Positive Sentiment Score: 75/100

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

Friday, July 25, 2025 1 min read
Key Takeaway: Celcuity Inc. has announced a conference call and webcast scheduled for July 28, 2025, to reveal the topline results from its Phase 3 VIKTORIA-1 trial focused on the PIK3CA Wild-Type Cohort in HR+/HER2- advanced breast cancer. This event is expected to provide crucial data on the efficacy of targeted therapies developed by the company. The results may significantly influence treatment approaches for this particular breast cancer subtype.

Market Sentiment Analysis

POSITIVE FACTORS

  • Celcuity is moving forward with an important clinical trial, indicating progress in their research.
  • The Phase 3 VIKTORIA-1 trial results may provide valuable insights for targeted therapies in oncology.
  • The announcement includes plans for a conference call and webcast, suggesting transparency and engagement with stakeholders.

Full Press Release Details

MINNEAPOLIS, July 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the Company will hold a conference call and webcast on Monday, July 28, 2025 at 8:00 AM ET to disclose the topline results of the PIK3CA Wild-Type Cohort from the Phase 3 VIKTORIA-1 trial.
Webcast and Conference Call Information
The Celcuity management team will host a webcast/conference call on Monday, July 28, 2025 at 8:00 a.m. ET to discuss the topline results from the Phase 3 VIKTORIA-1 trial. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. A replay of the webcast will be available on the Celcuity website following the live event.
View source version of release on GlobeNewswire.com
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
Patti Bank, patti.bank@icrhealthcare.com

Frequently Asked Questions

When is Celcuity's conference call about the VIKTORIA-1 trial?

The conference call is scheduled for Monday, July 28, 2025, at 8:00 AM ET.

What will be discussed in the Celcuity conference call?

The call will disclose the topline results from the PIK3CA Wild-Type Cohort in the VIKTORIA-1 trial.

How can I access the Celcuity webcast?

You can access the live webcast through the link provided by Celcuity.

Will there be a replay of the conference call?

Yes, a replay of the webcast will be available on the Celcuity website after the event.

Tags: CELC Viatris Investor Conferences Healthcare Celcuity PIK3CA advanced breast cancer VIKTORIA-1 oncology
Last updated: Jul 25, 2025